RnRMarketResearch.com adds “Growth Hormone Deficiency - Pipeline Review, H1 2015” to its store. The report provides an overview of the Growth Hormone Deficiency’s therapeutic pipeline.
Dallas, TX -- (SBWIRE) -- 02/02/2015 -- The report "Growth Hormone Deficiency - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for growth hormone deficiency. Growth hormone deficiency is a disorder that involves the pituitary gland which produces growth hormone and other hormones. Growth hormone deficiency has a multiplicity of unusual negative effects at different ages. The most common cause of growth hormone deficiency is pituitary and parasellar tumors. A person who has too little adult growth hormone will have symptoms that include a higher level of body fat, especially around the waist, anxiety and depression, decreased sexual function and interest, fatigue, feelings of being isolated from other people, greater sensitivity to heat and cold, less muscle (lean body mass), less strength, stamina and ability to exercise without taking a rest, reduced bone density and a tendency to have more bone fractures as they get older, changes in the makeup of the blood cholesterol. Treatment involves growth hormone injections given at home. Complete Report is Available @ http://www.rnrmarketresearch.com/growth-hormone-deficiency-pipeline-review-h1-2015-market-report.html .
It also reviews key players involved in the therapeutic development for growth hormone deficiency and special features on late-stage and discontinued projects. Companies discussed in this Growth Hormone Deficiency Pipeline Review H1 2015 report include Aeterna Zentaris Inc., Aileron Therapeutics, Inc., Ascendis Pharma A/S, Biogenomics Limited, Bolder Biotechnology, Inc., Braasch Biotech LLC, CJ CheilJedang Corp., Critical Pharmaceuticals Limited, Delpor, Inc., Emisphere Technologies, Inc., Flamel Technologies S.A., Genexine, Inc., HanAll Biopharma Co., Ltd., Hanmi Pharmaceuticals, Co. Ltd., Inbiopro Solutions Pvt. Ltd., LG Life Sciences, Ltd., OPKO Health, Inc., Pfenex Inc., Prometheon Pharma, LLC, Teva Pharmaceutical Industries Limited, Versartis, Inc., XL-protein GmbH.
The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269550 . (This is a premium report priced at US$2000 for a single user License.)
Featured News & Press Releases:
- Dec 29, 2014: Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study
- Dec 15, 2014: Ascendis Pharma Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency
- Oct 30, 2014: Versartis Schedules Conference Call to Discuss Plans for Phase 3 Trial for VRS-317 in Pediatric Growth Hormone Deficiency Patients
- Sep 18, 2014: Prometheon''s CEO/CSO Invited to Deliver Oral Presentation at the European Society for Paediatric Endocrinology Meeting
- Sep 16, 2014: Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency
- Sep 11, 2014: Data Supporting Once-Weekly Dosing of hGH-CTP in Growth Hormone Deficient Pediatric Population to be Presented as a Late Breaking Presentation at the European Society of Paediatric Endocrinology Conference
- Jun 30, 2014: Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317 105
- Jun 27, 2014: OPKO Granted Patent from European Patent Office for Lagova
- Jun 25, 2014: Strong Data from Lagova Phase II Clinical Study Presented during Webcast
- Jun 23, 2014: OPKO Announces Positive Interim Six-Month Lagova (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder
Inquiry before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=269550 . (This is a premium report priced at US$2000 for a single user License.)
Table of Contents
List of Figures
Number of Products under Development for Growth Hormone Deficiency, H1 2015
Number of Products under Development for Growth Hormone Deficiency – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Explore more reports on Pharmaceuticals industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.